Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib

Pediatric Low-Grade Ganglioglioma

(2015) Roy W.R. Dudley et al.   NEUROSURGERY

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

(2014) G. Kim et al.   CLINICAL CANCER RESEARCH

Successful Treatment With Dabrafenib (GSK2118436) in a Patient With Ganglioglioma

(2014) Kent C. Shih et al.   JOURNAL OF CLINICAL ONCOLOGY

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent

(2014) Francesca del Bufalo et al.   Journal of Translational Medicine

Pilomyxoid astrocytoma treated successfully with vemurafenib

(2014) Mary Skrypek et al.   PEDIATRIC BLOOD & CANCER

Posterior fossa and spinal gangliogliomas form two distinct clinicopathologic and molecular subgroups

(2014) Kirti Gupta et al.   Acta Neuropathologica Communications

Pediatric Brainstem Gangliogliomas ShowBRAFV600EMutation in a High Percentage of Cases

(2013) Andrew M. Donson et al.   BRAIN PATHOLOGY

Brainstem Ganglioglioma Successfully Treated With Vemurafenib

(2013) Sarah Rush et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib in pediatric patients withBRAFV600Emutated high-grade gliomas

(2013) Francisco Bautista et al.   PEDIATRIC BLOOD & CANCER

MEK in cancer and cancer therapy

(2013) Cindy Neuzillet et al.   PHARMACOLOGY & THERAPEUTICS